NIH PAR · NCI · U01
PAR-25-248: Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports…
- NOFO number
- PAR-25-248
- Type
- PAR
- Activity code
- U01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Not Allowed
- Posted
- Nov 21, 2024
- Opens
- Jan 10, 2025
- Expires
- Oct 9, 2027
PAR-25-248 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 10, 2025 | February 10, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 10, 2025 | June 10, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 10, 2025 | October 10, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 10, 2026 | February 10, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 10, 2026 | June 10, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 09, 2026 | October 09, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 10, 2027 | February 10, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 10, 2027 | June 10, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 08, 2027 | October 08, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-248
NIH RePORTER lists 3 projects funded under PAR-25-248 in FY2022–FY2026, with $2.1M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$2.1M
Award dollars under PAR-25-248, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 3 | $2.1M |
Institutions with the most funding
- Beckman Research Institute/City of Hope$739K · 1 project
- Vanderbilt University Medical Center$724K · 1 project
- Children's Hosp of Philadelphia$611K · 1 project
Funding institutes
- NCI$2.1M · 3
Activity codes funded
- U013 records
Most recent new awards
- Building lung cancer risk prediction models for former smokers: An omics-based epidemiologic study (opens NIH RePORTER)
Vanderbilt University Medical Center · 1U01CA312693-01 · NCI · Notice Sep 7, 2026
$724KU01
- Quantifiable TCR repertoire changes in pre-diagnostic blood specimens among high-grade ovarian cancer patients (opens NIH RePORTER)
Children's Hosp of Philadelphia · 1U01CA299369-01A1 · NCI · Notice Aug 28, 2026
$611KU01
- An exosome-based liquid biopsy assay for the non-invasive early detection of colorectal adenomas and cancers (opens NIH RePORTER)
Beckman Research Institute/City of Hope · 1U01CA299594-01A1 · NCI · Notice Mar 16, 2026
$739KU01
What its predecessor PAR-21-330 funded
PAR-25-248 reissues PAR-21-330. Its funding history is the best guide to who wins under this program: 6 projects and $8.4M in FY2022–FY2026.
Projects funded
6
Distinct projects, FY2022–FY2026
New awards
6
Type 1 (new project) award records
NIH funding
$8.4M
Award dollars under PAR-21-330, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 2 | 2 | $863K |
| FY2024 | 3 | 1 | $1.5M |
| FY2025 | 6 | 3 | $3.4M |
| FY2026 | 4 | 0 | $2.7M |
Institutions with the most funding
- University of Tx MD Anderson Can Ctr$3.2M · 2 projects
- Stanford University$1.9M · 1 project
- University of Chicago$1.4M · 1 project
- Beckman Research Institute/City of Hope$1.4M · 1 project
- Weizmann Institute of Science$552K · 1 project
Funding institutes
- NCI$8.4M · 15
Activity codes funded
- U0115 records
Most recent new awards
- 5mC and 5hmC DNA alterations as sensitive and specific biomarkers for the non-invasive early detection of pancreatic ductal adenocarcinoma (opens NIH RePORTER)
Beckman Research Institute/City of Hope · 1U01CA296639-01A1 · NCI · Notice Aug 26, 2025
$691KU01
- Validation of blood-based biomarkers for risk assessment of lung cancer among individuals with no smoking history in the PLCO Cohort (opens NIH RePORTER)
University of Tx MD Anderson Can Ctr · 1U01CA295902-01A1 · NCI · Notice Aug 25, 2025
$525KU01
- A non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis (opens NIH RePORTER)
University of Chicago · 1U01CA297685-01 · NCI · Notice Apr 23, 2025
$692KU01
- Single-molecule nanopore-based identification of methylome signatures in cfDNA for early colorectal cancer detection (opens NIH RePORTER)
Stanford University · 1U01CA282212-01A1 · NCI · Notice Aug 26, 2024
$640KU01
- Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer (opens NIH RePORTER)
University of Tx MD Anderson Can Ctr · 1U01CA282216-01 · NCI · Notice Sep 19, 2023
$672KU01
- Analysis of the predictability of lung cancer using DNA Repair functional assays and cryopreserved blood samples of the PLCO prospective cohort (opens NIH RePORTER)
Weizmann Institute of Science · 1U01CA279001-01 · NCI · Notice Apr 28, 2023
$191KU01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-248. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 1 NOSI to PAR-25-248; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewRenewalResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the project period. The maximum period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-21-330.
Other open NOFOs for U01
- RFA-CA-27-019Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)NCI · next due Oct 19, 2026
- PAR-25-325Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)NCI · next due Feb 4, 2027
- PAR-28-056Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-27-073Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-26-134The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)NCI · next due Jun 5, 2027
- PAR-24-325Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)NIBIB · next due Jan 27, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.